ArticlePharmacoEconomics2025

Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada.

Nick Jovanoski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.